Hearts and Minds Investments (ASX:HM1) said its revaluation of the holding value of Opthea (ASX: OPT) in its portfolio to AU$0.20 per share, will negatively impact its net asset value by about 1.6% or AU$0.056 per share, according to a Wednesday filing with the Australian bourse.
The revaluation takes into account the study results, as well as the potential for a "positive outcome" from the upcoming trial readout.
The company confirmed that it held a 2.4% stake in Opthea prior to the biopharmaceutical company's results of its study, the filing said.
Opthea said Monday that its Combination OPT-302 with Aflibercept (COAST) study in patients with age-related Macular Degeneration, failed to meet its primary endpoint and added there is significant doubt about its ability to continue as a going concern.
Shares of the company rose 1% in recent Wednesday trade.
Price (AUD): $3.05, Change: $+0.040, Percent Change: +1.33%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。